Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
TP5, a pentapeptide containing the active site of thymopoietin, was administered to five adult patients with CVH subcutaneously three times weekly for periods of 3 to 5 months. No significant consistent changes in lymphocyte cell surface markers or serum immunoglobulin levels were recorded; however, three of the five patients showed apparent partial reversal of in vitro suppressor T cell activity. In two of these three patients, initial skin test anergy showed temporary reversal during TP5 treatment. Two patients also showed an increase in ability of their B cells to synthesize lg in vitro when co-cultured with autologous or isologous T cells from normal donors. These changes did not persist after withdrawal of TP5 treatment.
D000328:Adult; D000361:Agammaglobulinemia / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D008213:Lymphocyte Activation; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D012882:Skin Tests; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D016305:Thymopentin; D013946:Thymopoietins / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*; D013997:Time Factors
D007136:Immunoglobulins; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin